Pazopanib(also known as Votrient, GW786034B, GSK-VEG10003) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (Flk-1), platelet-derived growth factor receptor (PDGFR) and c-kit, which blocks tumour growth and inhibits angiogenesis. It is typically used to treat renal cell carcinoma and soft tissue sarcoma.
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Comprehensive analysis of kinase inhibitor selectivity.
Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.